Content Library
An Interview Chat With Namir Hassan, CEO, Zelluna Immunotherapy
In this exclusive interview, Namir discusses:
- The biggest hurdles in the development of solid tumor treatment
- How Zelluna Immunotherapy are trying to overcome these challenges
- How Zelluna's work with TCRs and NK cells is unique and more!
An Overview of the TCR Field: Challenges & Current Progress
TCR-based therapies hold great potential for treatment options in solid tumor indications. This TCR package is a must-read to prepare you, covering:
- YoY growth of TCR-T trials
- Breakdown of trials by antigen type
- Overview of the key challenges in TCR-T development
- The who’s who of TCR-T problem-solving
- Phase distribution of TCR-T trials and competitive landscape
Industry Insights - Gang Zeng
Finding T-Cure: A CEO’s vision for the future of adoptive cell immunotherapy